Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4918479 | 0.99 | DPP4 (0.47) | DPP4DPP8DPP9CYP3A4HSD11B1 | |
| SCHEMBL5187409 | 0.92 | DPP4 (0.44) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL4913608 | 0.91 | DPP4 (0.43) | DPP4DPP8DPP9 | |
| SCHEMBL5202471 | 0.90 | DPP4 (0.55) | DPP4DPP8DPP9CYP3A4 | |
| Hydrochloric Acid SCHEMBL4912438 | 0.89 | DPP4 (0.54) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL4911607 | 0.88 | HSD11B1 (0.43) | DPP4DPP8DPP9HSD11B1 | |
| SCHEMBL19835409 | 0.87 | MALT1 (0.50) | DPP4DPP8DPP9CYP3A4 | |
| SCHEMBL4911902 | 0.86 | MALT1 (0.43) | DPP4DPP8HSD11B1 | |
| SCHEMBL3106224 | 0.83 | DPP4 (0.47) | DPP4 | |
| SCHEMBL3114608 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1805143-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006042955-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CNR1, CNR2, GPR18 | DPP4 3899/4885DPP8 4105/4885DPP9 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.